

May 09, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Update on Glenmark's Indore manufacturing facility

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to intimation dated 14th February, 2025 for United States Food and Drug Administration (USFDA) inspection of our Indore, Madhya Pradesh manufacturing facility, we wish to inform you that the Company has received a communication from the US FDA indicating the inspection classification as "Official Action Indicated" (OAI). We will work closely with the US FDA to achieve a fully compliant status. This is for your information and dissemination.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer